α-Muricholic Acid
(Synonyms: 5β-Cholanic Acid-3α,6β,7α-triol) 目录号 : GC40718A murine-specific primary bile acid
Cas No.:2393-58-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
α-Muricholic acid is a murine-specific primary bile acid.[1] Dietary administration of soybean protein decreases fecal levels of α-muricholic acid in mice with high-fat diet-induced obesity which correlates with increases in fecal Clostridium cluster XIVa, a major producer of secondary bile acids.[2] [3] Plasma, liver, and muscle levels of α-muricholic acid are increased in mice switched from a high-fat to low-fat diet.[4]
Reference:
[1]. Eyssen, H.J., Parmentier, G.G., and Mertens, J.A. Sulfate bile acids in germ-free and conventional mice. Eur. J. Biochem. 66(3), 507-514 (1976).
[2]. Uehara, T., Xi Peng, X., Bennett, B., et al. c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation 78(3), 324-332 (2004).
[3]. Watanabe, K., Igarashi, M., Li, X., et al. Dietary soybean protein ameliorates high-fat diet-induced obesity by modifying the gut microbiota-dependent biotransformation of bile acids. PLoS One 13(8), e0202083 (2018).
[4]. La Frano, M.R., Hernandez-Carretero, A., Weber, N., et al. Diet-induced obesity and weight loss alter bile acid concentrations and bile acid-sensitive gene expression in insulin target tissues of C57BL/6J mice. Nutr. Res. 46, 11-21 (2017).
Cas No. | 2393-58-0 | SDF | |
别名 | 5β-Cholanic Acid-3α,6β,7α-triol | ||
化学名 | (3α,5β,6β,7α)-3,6,7-trihydroxy-cholan-24-oic acid | ||
Canonical SMILES | C[C@H](CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)[C@@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
分子式 | C24H40O5 | 分子量 | 408.6 |
溶解度 | 20mg/mL in ethanol, or in DMSO, 30mg/mL in DMF | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4474 mL | 12.2369 mL | 24.4738 mL |
5 mM | 0.4895 mL | 2.4474 mL | 4.8948 mL |
10 mM | 0.2447 mL | 1.2237 mL | 2.4474 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。